The role of maintenance chemotherapy in advanced nonsmall cell lung cancer

Shadia Jalal, Foluso O. Ademuyiwa, Nasser Hanna

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose of review Advanced nonsmall cell lung cancer (NSCLC) remains a therapeutic challenge. Traditional chemotherapy provides response rates of about 20-40% and median survivals of 8-10 months. The outcome of patients presenting at an advanced stage is therefore disappointing. In order to improve patients' outcomes, there has been a renewed interest in evaluating the role of maintenance or consolidation chemotherapy or both. Therefore, this review is timely and also relevant to clinical practice. Recent findings Thirteen randomized clinical trials have reported that consolidation or maintenance therapy or both improves progression free survival in patients with advanced NSCLC who have achieved disease control following their initial therapy. This does not translate into survival benefits in the same patient populations. Furthermore, prolonged therapy results in more treatment-related toxicity without improvements in quality of life as documented in 11 of these trials. We summarize the current data and perspectives of consolidation/maintenance therapy in patients with advanced NSCLC. Summary Completed trials evaluating consolidation or maintenance therapy or both in patients with advanced NSCLC consistently demonstrate that this strategy will improve progression free survival but not overall survival. Administering maintenance or consolidation therapy to patients with advanced NSCLC to improve progression free survival alone is not recommended.

Original languageEnglish
Pages (from-to)110-115
Number of pages6
JournalCurrent Opinion in Oncology
Volume21
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Maintenance Chemotherapy
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Therapeutics
Survival
Consolidation Chemotherapy
Randomized Controlled Trials
Maintenance
Quality of Life
Drug Therapy

Keywords

  • Lung cancer
  • Maintenance/consolidation chemotherapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. / Jalal, Shadia; Ademuyiwa, Foluso O.; Hanna, Nasser.

In: Current Opinion in Oncology, Vol. 21, No. 2, 03.2009, p. 110-115.

Research output: Contribution to journalArticle

@article{65e2cfab8e5e4d61854d1e710d35ea72,
title = "The role of maintenance chemotherapy in advanced nonsmall cell lung cancer",
abstract = "Purpose of review Advanced nonsmall cell lung cancer (NSCLC) remains a therapeutic challenge. Traditional chemotherapy provides response rates of about 20-40{\%} and median survivals of 8-10 months. The outcome of patients presenting at an advanced stage is therefore disappointing. In order to improve patients' outcomes, there has been a renewed interest in evaluating the role of maintenance or consolidation chemotherapy or both. Therefore, this review is timely and also relevant to clinical practice. Recent findings Thirteen randomized clinical trials have reported that consolidation or maintenance therapy or both improves progression free survival in patients with advanced NSCLC who have achieved disease control following their initial therapy. This does not translate into survival benefits in the same patient populations. Furthermore, prolonged therapy results in more treatment-related toxicity without improvements in quality of life as documented in 11 of these trials. We summarize the current data and perspectives of consolidation/maintenance therapy in patients with advanced NSCLC. Summary Completed trials evaluating consolidation or maintenance therapy or both in patients with advanced NSCLC consistently demonstrate that this strategy will improve progression free survival but not overall survival. Administering maintenance or consolidation therapy to patients with advanced NSCLC to improve progression free survival alone is not recommended.",
keywords = "Lung cancer, Maintenance/consolidation chemotherapy, Tyrosine kinase inhibitors",
author = "Shadia Jalal and Ademuyiwa, {Foluso O.} and Nasser Hanna",
year = "2009",
month = "3",
doi = "10.1097/CCO.0b013e328322cf49",
language = "English",
volume = "21",
pages = "110--115",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The role of maintenance chemotherapy in advanced nonsmall cell lung cancer

AU - Jalal, Shadia

AU - Ademuyiwa, Foluso O.

AU - Hanna, Nasser

PY - 2009/3

Y1 - 2009/3

N2 - Purpose of review Advanced nonsmall cell lung cancer (NSCLC) remains a therapeutic challenge. Traditional chemotherapy provides response rates of about 20-40% and median survivals of 8-10 months. The outcome of patients presenting at an advanced stage is therefore disappointing. In order to improve patients' outcomes, there has been a renewed interest in evaluating the role of maintenance or consolidation chemotherapy or both. Therefore, this review is timely and also relevant to clinical practice. Recent findings Thirteen randomized clinical trials have reported that consolidation or maintenance therapy or both improves progression free survival in patients with advanced NSCLC who have achieved disease control following their initial therapy. This does not translate into survival benefits in the same patient populations. Furthermore, prolonged therapy results in more treatment-related toxicity without improvements in quality of life as documented in 11 of these trials. We summarize the current data and perspectives of consolidation/maintenance therapy in patients with advanced NSCLC. Summary Completed trials evaluating consolidation or maintenance therapy or both in patients with advanced NSCLC consistently demonstrate that this strategy will improve progression free survival but not overall survival. Administering maintenance or consolidation therapy to patients with advanced NSCLC to improve progression free survival alone is not recommended.

AB - Purpose of review Advanced nonsmall cell lung cancer (NSCLC) remains a therapeutic challenge. Traditional chemotherapy provides response rates of about 20-40% and median survivals of 8-10 months. The outcome of patients presenting at an advanced stage is therefore disappointing. In order to improve patients' outcomes, there has been a renewed interest in evaluating the role of maintenance or consolidation chemotherapy or both. Therefore, this review is timely and also relevant to clinical practice. Recent findings Thirteen randomized clinical trials have reported that consolidation or maintenance therapy or both improves progression free survival in patients with advanced NSCLC who have achieved disease control following their initial therapy. This does not translate into survival benefits in the same patient populations. Furthermore, prolonged therapy results in more treatment-related toxicity without improvements in quality of life as documented in 11 of these trials. We summarize the current data and perspectives of consolidation/maintenance therapy in patients with advanced NSCLC. Summary Completed trials evaluating consolidation or maintenance therapy or both in patients with advanced NSCLC consistently demonstrate that this strategy will improve progression free survival but not overall survival. Administering maintenance or consolidation therapy to patients with advanced NSCLC to improve progression free survival alone is not recommended.

KW - Lung cancer

KW - Maintenance/consolidation chemotherapy

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=62349108713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62349108713&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328322cf49

DO - 10.1097/CCO.0b013e328322cf49

M3 - Article

VL - 21

SP - 110

EP - 115

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -